116 related articles for article (PubMed ID: 38159995)
1. Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells
Oka D; Sekine Y; Tsuji Y; Nakayama H; Miyazawa Y; Arai S; Koike H; Suzuki K
Anticancer Res; 2024 Jan; 44(1):93-98. PubMed ID: 38159995
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer Cells.
Miyazawa Y; Sekine Y; Oka D; Nakazawa S; Tsuji Y; Nakayama H; Suzuki K
Anticancer Res; 2023 Dec; 43(12):5377-5386. PubMed ID: 38030198
[TBL] [Abstract][Full Text] [Related]
5. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
Young A; Berry R; Holloway AF; Blackburn NB; Dickinson JL; Skala M; Phillips JL; Brettingham-Moore KH
BMC Cancer; 2014 Nov; 14():808. PubMed ID: 25369795
[TBL] [Abstract][Full Text] [Related]
6. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad U; Abbas T; Dutta A
Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism.
Sekine Y; Demosky SJ; Stonik JA; Furuya Y; Koike H; Suzuki K; Remaley AT
Mol Cancer Res; 2010 Sep; 8(9):1284-94. PubMed ID: 20671065
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.
Sekine Y; Nakayama H; Miyazawa Y; Kato H; Furuya Y; Arai S; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Oncol Lett; 2018 Mar; 15(3):3167-3172. PubMed ID: 29435052
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins.
Furuya Y; Sekine Y; Kato H; Miyazawa Y; Koike H; Suzuki K
Prostate Int; 2016 Jun; 4(2):56-60. PubMed ID: 27358845
[TBL] [Abstract][Full Text] [Related]
11. Effect of simvastatin on castration-resistant prostate cancer cells.
Kim JH; Cox ME; Wasan KM
Lipids Health Dis; 2014 Mar; 13():56. PubMed ID: 24666612
[TBL] [Abstract][Full Text] [Related]
12. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
Syvälä H; Pennanen P; Bläuer M; Tammela TL; Murtola TJ
Biochem Biophys Res Commun; 2016 Dec; 481(1-2):46-50. PubMed ID: 27833018
[TBL] [Abstract][Full Text] [Related]
13. Modulation of radiosensitivity of DU145 prostate carcinoma cells by simvastatin.
Korte V; Gademann G; Gawish A; Ochel HJ
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4509-4514. PubMed ID: 36127484
[TBL] [Abstract][Full Text] [Related]
14. Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.
Mirzaei A; Rashedi S; Akbari MR; Khatami F; Aghamir SMK
J Cell Mol Med; 2022 May; 26(9):2728-2740. PubMed ID: 35366048
[TBL] [Abstract][Full Text] [Related]
15. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
16. In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol.
Hermann RM; Wolff HA; Jarry H; Thelen P; Gruendker C; Rave-Fraenk M; Schmidberger H; Christiansen H
Radiat Oncol; 2008 Jul; 3():19. PubMed ID: 18625043
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Zheng X; Cui XX; Gao Z; Zhao Y; Lin Y; Shih WJ; Huang MT; Liu Y; Rabson A; Reddy B; Yang CS; Conney AH
Cancer Prev Res (Phila); 2010 Jan; 3(1):114-24. PubMed ID: 20051379
[TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.
Murtola TJ; Pennanen P; Syvälä H; Bläuer M; Ylikomi T; Tammela TL
Prostate; 2009 Jun; 69(9):1017-23. PubMed ID: 19301305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
